Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease

Steven MacLennan; Alberto Briganti; Jeremy M Grimshaw; James N'Dow

doi:10.1016/j.eururo.2016.12.019

Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease

Steven MacLennan, Alberto Briganti, Jeremy M Grimshaw, James N'Dow

Research output: Contribution to journal › Comment/debate

1 Citation (Scopus)

8 Downloads (Pure)

Abstract

The authors address the thorny issue of the lack of adherence to Clinical Practice Guidelines highlighting high-quality evidence based nonmuscle-invasive bladder cancer (NMIBC) guideline recommendations from the American Urological Association/Society of Urologic Oncology, and the European Association of Urology as exemplars [1]. In particular, they emphasise three strong practice recommendations underpinned by high-quality evidence: immediate intravesical installation of chemotherapy in patients with presumed low-risk or intermediate-risk NMIBC, the performance of a second transurethral resection for high-risk NMIBC, and the administration of adjuvant intravesical Bacillus Calmette–Guérin immunotherapy in high-risk NMIBC. Data from North America, Europe, and Australia are cited illustrating variability and general lack of adherence (ranging from 0.5% to 65%) to these recommendations.

Original language	English
Pages (from-to)	689
Number of pages	1
Journal	European Urology
Volume	71
Issue number	4
Early online date	28 Dec 2016
DOIs	https://doi.org/10.1016/j.eururo.2016.12.019
Publication status	Published - 1 Apr 2017

Access to Document

10.1016/j.eururo.2016.12.019Licence: Unspecified

Accepted Manuscript
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Accepted author manuscript, 811 KBLicence: CC BY-NC-ND

Fingerprint Dive into the research topics of 'Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease'. Together they form a unique fingerprint.

Cite this

@article{8a065415cc9d4bcbb43eea7a02a849a2,

title = "Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease",

abstract = "The authors address the thorny issue of the lack of adherence to Clinical Practice Guidelines highlighting high-quality evidence based nonmuscle-invasive bladder cancer (NMIBC) guideline recommendations from the American Urological Association/Society of Urologic Oncology, and the European Association of Urology as exemplars [1]. In particular, they emphasise three strong practice recommendations underpinned by high-quality evidence: immediate intravesical installation of chemotherapy in patients with presumed low-risk or intermediate-risk NMIBC, the performance of a second transurethral resection for high-risk NMIBC, and the administration of adjuvant intravesical Bacillus Calmette–Gu{\'e}rin immunotherapy in high-risk NMIBC. Data from North America, Europe, and Australia are cited illustrating variability and general lack of adherence (ranging from 0.5% to 65%) to these recommendations.",

author = "Steven MacLennan and Alberto Briganti and Grimshaw, {Jeremy M} and James N'Dow",

year = "2017",

month = apr,

day = "1",

doi = "10.1016/j.eururo.2016.12.019",

language = "English",

volume = "71",

pages = "689",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease

AU - MacLennan, Steven

AU - Briganti, Alberto

AU - Grimshaw, Jeremy M

AU - N'Dow, James

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The authors address the thorny issue of the lack of adherence to Clinical Practice Guidelines highlighting high-quality evidence based nonmuscle-invasive bladder cancer (NMIBC) guideline recommendations from the American Urological Association/Society of Urologic Oncology, and the European Association of Urology as exemplars [1]. In particular, they emphasise three strong practice recommendations underpinned by high-quality evidence: immediate intravesical installation of chemotherapy in patients with presumed low-risk or intermediate-risk NMIBC, the performance of a second transurethral resection for high-risk NMIBC, and the administration of adjuvant intravesical Bacillus Calmette–Guérin immunotherapy in high-risk NMIBC. Data from North America, Europe, and Australia are cited illustrating variability and general lack of adherence (ranging from 0.5% to 65%) to these recommendations.

AB - The authors address the thorny issue of the lack of adherence to Clinical Practice Guidelines highlighting high-quality evidence based nonmuscle-invasive bladder cancer (NMIBC) guideline recommendations from the American Urological Association/Society of Urologic Oncology, and the European Association of Urology as exemplars [1]. In particular, they emphasise three strong practice recommendations underpinned by high-quality evidence: immediate intravesical installation of chemotherapy in patients with presumed low-risk or intermediate-risk NMIBC, the performance of a second transurethral resection for high-risk NMIBC, and the administration of adjuvant intravesical Bacillus Calmette–Guérin immunotherapy in high-risk NMIBC. Data from North America, Europe, and Australia are cited illustrating variability and general lack of adherence (ranging from 0.5% to 65%) to these recommendations.

U2 - 10.1016/j.eururo.2016.12.019

DO - 10.1016/j.eururo.2016.12.019

M3 - Comment/debate

C2 - 28040355

VL - 71

SP - 689

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 4

ER -